BRPI0910735A2 - uso de um derivado de benzofenona e de um ou mais agentes imunossupressores em combinação, composição farmacéutica para o tratamento de doenças autoimunes, e, kit - Google Patents

uso de um derivado de benzofenona e de um ou mais agentes imunossupressores em combinação, composição farmacéutica para o tratamento de doenças autoimunes, e, kit

Info

Publication number
BRPI0910735A2
BRPI0910735A2 BRPI0910735A BRPI0910735A BRPI0910735A2 BR PI0910735 A2 BRPI0910735 A2 BR PI0910735A2 BR PI0910735 A BRPI0910735 A BR PI0910735A BR PI0910735 A BRPI0910735 A BR PI0910735A BR PI0910735 A2 BRPI0910735 A2 BR PI0910735A2
Authority
BR
Brazil
Prior art keywords
kit
treatment
combination
pharmaceutical composition
autoimmune diseases
Prior art date
Application number
BRPI0910735A
Other languages
English (en)
Inventor
Shiozawa Shunichi
Aikawa Yukihiko
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of BRPI0910735A2 publication Critical patent/BRPI0910735A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0910735A 2008-04-22 2009-04-20 uso de um derivado de benzofenona e de um ou mais agentes imunossupressores em combinação, composição farmacéutica para o tratamento de doenças autoimunes, e, kit BRPI0910735A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008111295 2008-04-22
PCT/JP2009/057860 WO2009131098A1 (ja) 2008-04-22 2009-04-20 ベンゾフェノン誘導体またはその塩および免疫抑制剤を組み合わせて使用する方法ならびにこれらを含有する医薬組成物

Publications (1)

Publication Number Publication Date
BRPI0910735A2 true BRPI0910735A2 (pt) 2019-09-24

Family

ID=41216830

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910735A BRPI0910735A2 (pt) 2008-04-22 2009-04-20 uso de um derivado de benzofenona e de um ou mais agentes imunossupressores em combinação, composição farmacéutica para o tratamento de doenças autoimunes, e, kit

Country Status (21)

Country Link
US (1) US9066977B2 (pt)
EP (1) EP2266557B1 (pt)
JP (2) JP5512511B2 (pt)
KR (1) KR101525851B1 (pt)
CN (2) CN102014889A (pt)
AU (1) AU2009239053B2 (pt)
BR (1) BRPI0910735A2 (pt)
CA (1) CA2721920A1 (pt)
CY (1) CY1114378T1 (pt)
DK (1) DK2266557T3 (pt)
ES (1) ES2429592T3 (pt)
HR (1) HRP20130859T1 (pt)
IL (1) IL208622A0 (pt)
MX (1) MX2010011666A (pt)
NZ (1) NZ588470A (pt)
PL (1) PL2266557T3 (pt)
PT (1) PT2266557E (pt)
RU (1) RU2496490C2 (pt)
SI (1) SI2266557T1 (pt)
WO (1) WO2009131098A1 (pt)
ZA (1) ZA201007133B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240891A1 (en) 2007-09-28 2010-09-23 Toyama Chemical Co., Ltd. Drug containing benzophenone derivative or its salt
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CN118255728B (zh) * 2024-01-25 2024-07-30 中国医学科学院阜外医院 化合物的盐型晶型用于治疗射血分数保留的心衰的用途
CN118252824B (zh) * 2024-01-25 2024-09-17 中国医学科学院阜外医院 化合物用于治疗射血分数保留的心衰的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2228557T3 (es) * 1999-07-16 2005-04-16 Leo Pharma A/S Aminobenzofenonas con inhibidores de la il-1beta y tnf-alfa.
RU2270194C2 (ru) * 2000-05-22 2006-02-20 Лео Фарма А/С Бензофеноны как ингибиторы il-1бета и tnf-альфа, фармацевтическая композиция и способ лечения
US6608101B1 (en) 2000-06-20 2003-08-19 Atherogenics, Inc. 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
JP2003040776A (ja) 2001-05-24 2003-02-13 Sankyo Co Ltd 関節炎を予防若しくは治療するための医薬組成物
DK1445249T3 (da) * 2001-11-16 2012-12-17 Toyama Chemical Co Ltd Nye bensophenon-derivater eller salte deraf
TW200500065A (en) 2003-05-21 2005-01-01 Wyeth Corp Antiarthritic combinations
CA2643052C (en) 2006-02-21 2014-02-11 Toyama Chemical Co., Ltd. Process for production of 3-[5-[4-(cyclopentyloxy)-2-hydroxybenzoyl]-2-[(3-oxo-2-substituted-2,3-dihydro-1,2-benzisoxazol-6-yl)methoxy]phenyl]propionate ester and intermediate forthe process
ES2463455T3 (es) 2006-05-26 2014-05-28 Toyama Chemical Co., Ltd. Composición oral que comprende ácido 3-{5-[4-(ciclopentiloxi)-2-hidroxibenzoil]-2-[(3-hidroxi-1,2-benzisoxazol-6-il)metoxi]fenil}propiónico o una de sus sales
MX2008014906A (es) 2006-05-26 2008-12-09 Toyama Chemical Co Ltd Cristal novedoso de acido propionico de 3[5-(4-ciclopentiloxi)-2-h idroxibenzoilo]-2-[(3-hidroxi-1,2-benzisozazol-6-ilo)metoxi]-feni lo].
US20100240891A1 (en) 2007-09-28 2010-09-23 Toyama Chemical Co., Ltd. Drug containing benzophenone derivative or its salt

Also Published As

Publication number Publication date
WO2009131098A1 (ja) 2009-10-29
EP2266557B1 (en) 2013-08-14
AU2009239053B2 (en) 2014-04-03
ES2429592T3 (es) 2013-11-15
AU2009239053A1 (en) 2009-10-29
JP2014166984A (ja) 2014-09-11
ZA201007133B (en) 2011-12-28
IL208622A0 (en) 2010-12-30
EP2266557A4 (en) 2011-09-21
NZ588470A (en) 2012-12-21
JP5512511B2 (ja) 2014-06-04
JP5698830B2 (ja) 2015-04-08
KR20110025167A (ko) 2011-03-09
PT2266557E (pt) 2013-09-30
JPWO2009131098A1 (ja) 2011-08-18
CN102920711A (zh) 2013-02-13
SI2266557T1 (sl) 2013-12-31
EP2266557A1 (en) 2010-12-29
KR101525851B1 (ko) 2015-06-04
MX2010011666A (es) 2010-12-06
CN102014889A (zh) 2011-04-13
CY1114378T1 (el) 2016-08-31
PL2266557T3 (pl) 2013-12-31
HRP20130859T1 (hr) 2013-10-11
RU2010147396A (ru) 2012-05-27
US9066977B2 (en) 2015-06-30
RU2496490C2 (ru) 2013-10-27
DK2266557T3 (da) 2013-09-23
CA2721920A1 (en) 2009-10-29
US20110039813A1 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
CR8642A (es) Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
BRPI0918492A2 (pt) uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
BRPI0922233A2 (pt) compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0618845A2 (pt) composto, formulação farmacêutica, uso de um composto, e, métodos para a inibição da atividade de bace e para o tratamento ou a prevenção de uma patologia relacionada a abeta em um mamífero
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI0820899A2 (pt) Formulação cosmética, e, uso da composição
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
BR112014002718A2 (pt) célula, população de célula, composição farmacêutica e kit para uso no tratamento de uma doença de degeneraçãoretinal
BRPI0813456A2 (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para tratar um mamífero sofrendo de um distúrbio e de uma doença
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
BRPI0914863A2 (pt) formulação tópica estável, e, uso da mesma
BRPI0813955A2 (pt) composições terapêuticas e o uso das mesmas
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
BRPI0813828A2 (pt) Compostos antimicrobianos, a síntese dos mesmos e o uso dos mesmos para o tratamento de infecções em mamíferos
BRPI0915552A2 (pt) derivados de ciclosporina, seu uso e sua composição farmacêutica
BRPI0911203A2 (pt) peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.